10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
Swiss pharma giant Roche has presented data from the largest pivotal study to date in children with hemophilia A at the American Society of Hematology Annual Meeting. 4 December 2018
German biotech Evotec has entered into a new integrated drug discovery alliance with Denmark’s LEO Pharma, a global leader in medical dermatology, adding to a string of deals the German company has signed this year. 4 December 2018
BeiGene clinical data from the pivotal Phase II trial of its investigational anti-PD-1 antibody, tislelizumab, in Chinese patients with relapsed/refractory (R/R) classical Hodgkin’s lymphoma (cHL), at the Annual Meeting of the American Society of Hematology (ASH) yesterday. 4 December 2018
Japanese biopharma Sosei Group has announced a re-branding and re-launching of its main operating business, three years after paying $400 million for Heptares Therapeutics’ G protein-coupled receptor pipeline. 3 December 2018
UK Research and Innovation (UKRI) has announced it will build a new Vaccines Manufacturing Innovation Centre, aimed at addressing a “structural gap in late-stage vaccine manufacturing process development.” 3 December 2018
There has been much speculation in recent weeks that US drugmaker and PARP inhibitor specialist Tesaro had put itself up for sale that has already sent the firm’s shares higher, but today they leapt more than 59% to $73.95 in pre-market trading after it was revealed that it has reached agreement to be taken over. 3 December 2018
US biotech firm Seattle Genetics’ shares gained 2.75% to $64.3-in pre-market trading today, after it highlighted data from the ECHELON-1 Phase III clinical trial evaluating Adcetris (brentuximab vedotin) at the ASH meeting. 3 December 2018
China’s BeiGene on Saturday announced clinical data from two ongoing trials of its investigational Bruton’s tyrosine kinase (BTK) inhibitor, zanubrutinib, in patients with mantle cell lymphoma (MCL), at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place December 1-4, 2018 in San Diego, USA. 3 December 2018
Gilead Sciences company Kite Pharma released positive two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. 3 December 2018
In a Phase III clinical trial, presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, USA, on the opening day, December 1, the experimental drug luspatercept significantly reduced the need for blood transfusions in patients with the inherited blood disorder beta thalassemia. 2 December 2018
Ireland-incorporated rare disease specialist Shire has been granted European approval for Takhzyro (lanadelumab) for routine prevention of attacks of hereditary angioedema (HAE), a rare, genetic and potentially life-threatening disorder. 30 November 2018
Bristol-Myers Squibb has entered a collaboration with two UK partners that comes with the promise of creating a ‘rule book’ to guide precision combination immunotherapies and to speed up the development of new lung cancer treatments. 30 November 2018
UK medicines cost-effectiveness watchdog the National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the reimbursement within the Cancer Drugs Fund (CDF) of the immunotherapy, Opdivo (nivolumab), as adjuvant treatment after surgery, to potentially keep the cancer from returning. 30 November 2018
The growth of Chinese biopharma Hutchinson China MediTech took a dent earlier in the month with the share-damaging news of a Phase III failure of fruquintinib, a drug that has just been approved in China to treat advanced colorectal cancer. 29 November 2018
The US Food and Drug Administration on Wednesday approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. 29 November 2018
The US Food and Drug Administration has given Catalyst Pharmaceuticals approval for Firdapse (amifampridine), a therapy for the rare disease Lambert-Eaton myasthenic syndrome (LEMS). 29 November 2018
Charlotte Tillett, partner, and Emily Hocken, trainee, at Stevens & Bolton, offer an Expert View on the significance of the UK Supreme Court ruling in Warner-Lambert (WL) v Generics relating to WL’s best-selling pain relief drug, Lyrica (pregabalin). 28 November 2018
Hookipa Pharma has entered into a research collaboration and license agreement with DarwinHealth to develop novel immunotherapies based on the systematic discovery and prioritization of the next generation of immunogenic, tumor-specific cryptic antigens. 28 November 2018
The marketing drive for Shire’s Takhzyro (lanadelumab) has had a boost as the company seeks to convince payers that its hefty price tag is worth paying. 28 November 2018
US gene therapy company Rocket Pharmaceuticals yesterday announced that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) and fast track designations to RP-L102, the company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi anemia (FA). 28 November 2018
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024